Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Capri Holdings Ltd (CPRI) vs Stryker Corporation (SYK) Price & Performance

Capri Holdings LtdTrade
Stryker CorporationTrade

Price performance (Past 24H)

Key statistics

Capri Holdings Ltd vs Stryker Corporation — how do they compare? Capri Holdings Ltd trades at $14.95 (market cap $1.67B), while Stryker Corporation trades at $277.33 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 63.6× Capri Holdings Ltd's market cap, and Stryker Corporation pays a 1.27% dividend while Capri Holdings Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Capri Holdings Ltd for 41 Days and Stryker Corporation for 21 Days on average.

CPRISYK
Market Cap
$1.67B$106.24B
Volume
3,722,2792,982,001
Sector
Consumer CyclicalHealth
52-Week High
$27.66$388.35
52-Week Low
$12.71$269.75
Typical Hold Time
41 Days21 Days
Enterprise Value
$2.95B$117.70B
Dividend Yield
—1.27%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Capri Holdings Ltd

CPRI trades at $14.95, up 3.53% today, with a bullish technical signal from moving averages and recent positive earnings beats. The stock shows a low P/S of 0.51 and strong gross margins above 62%, but faces challenges with a net loss of $1.18 billion in 2025 and declining revenue trends. Recent news highlights management's focus on brand revitalization and second-half growth expectations for Michael Kors and Jimmy Choo.

The outlook is mixed: valuation appears attractive and earnings momentum is positive, but sustained revenue growth and margin recovery are critical for upside. Key risks include execution on the Michael Kors turnaround, competitive pressures, and macroeconomic sensitivity. The consensus price target of $20.57 suggests potential appreciation if operational improvements materialize.

Stryker Corporation

Stryker (SYK) trades at $277.33, up 0.7% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279, while fundamentals remain solid with a 14.43% net income margin and strong analyst consensus. Recent news highlights ongoing legal scrutiny related to a manufacturing issue disclosed in September 2026, which caused an 8.8% stock drop, but the company continues to innovate with product launches like Prophecy surgical planning.

The outlook for SYK is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities include robust profitability and growth in medical technology, but risks persist from legal investigations and potential operational disruptions. Investors should weigh strong analyst support against near-term sentiment headwinds.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CPRI
43% Buy57% Sell
Avg holding period · 41 Days
SYK

No sentiment data available yet.

Top news

Latest headlines on both assets

About Capri Holdings Ltd

Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.

Read more on CPRI →

About Stryker Corporation

Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.

Read more on SYK →